Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000154
Chunk: 37

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 37
---
,191 |
| Total                                                                                                                                                           |     |                                      | 2,384,028 |     |     | 2,219,481 |
| “Other” includes the Middle East, Oceania and Africa. This disaggregation provides revenue attributable to countries or regions based on the customer location. |     |                                      |           |     |     |           |

<div align='center'>- 33 -</div>

Translation for reference purpose only

5. Amortization and impairment losses on intangible assets associated with products

The impairment losses recorded for the six-month period ended September 30, 2024 was JPY 27,762 million, which included JPY 21,490 million impairment charge for soticlestat (TAK-935), following the failure of the Phase 3 studies to meet their primary endpoints.

The impairment losses recorded for the six-month period ended September 30, 2025 was JPY 76,042 million, which primarily included JPY 58,173 million of impairment charges related to the gamma delta T-cell therapy platform and associated Oncology program, and impairment charges for certain other in-process R&D assets, all of which were recorded following the decision to discontinue the related research and development activities.

#### 6. Other Operating Expenses
Other operating expenses for the six-month period ended September 30, 2024, included JPY 61,629 million of restructuring expenses, which mainly consisted of the costs related to the enterprise-wide efficiency program.

Other operating expenses for the six-month period ended September 30, 2025, included JPY 27,428 million of restructuring expenses, which mainly consisted of the costs related to the enterprise-wide efficiency program, and JPY 23,959 million of expenses recognized for the valuation reserve on pre-launch inventories.

#### 7. Income Tax Expenses
The effective tax rate for the six-month period ended September 30, 2025 was 37.1% compared to 26.8% for the six-month period ended September 30, 2024. The increase in the effective tax rate was primarily due to higher non-deductible expenses related to impairment losses and lower tax credits recognized during the six-month period ended September 30, 2025, partially offset by a reduction of tax expenses recognized in connection with the reassessment of the recoverability of deferred tax assets.

#### 8. Earnings per Share
The basis for calculating basic and diluted earnings per share (attributable to owners of the